Lucid Diagnostics
Jeri Harashima currently serves as the Director of Medical Policy at Lucid Diagnostics since December 2023. Prior experience includes roles as Director of Policy and Payer Relations at Hologic, Inc. from November 2021 to December 2023, and Director of Policy & Health Outcomes at Scipher Medicine from May 2020 to November 2021. Jeri also worked as a Medical Policy Manager at Myriad Genetics and as a Medical Policy Specialist at Counsyl. Earlier positions include Lead Oncology Genetic Counselor and Supervisor at Intermountain Healthcare, Product Manager at Lineagen, and Faculty II for the Graduate Program in Genetic Counseling at the University of Utah. Jeri earned a Master of Science in Genetic Counseling from the University of Utah School of Medicine and holds a Bachelor of Science in Genetics and Biotechnology from Brigham Young University, along with an Associate of Science in Biotechnology from Raritan Valley Community College.
This person is not in any teams
This person is not in any offices
Lucid Diagnostics
1 followers
Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc (Nasdaq: PAVM) that has breakthrough devices, EsoCheck and EsoGuard, for esophageal cell collection and diagnosis of Barrett's Esophagus.